Clinical trials: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Vaccines, Pneumococcal Conjugate Vaccine
Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
People who have received an allogeneic hematopoetic stem cell transplant (HSCT) are more likely than other people to get ill from a germ called Streptococcus pneumoniae.
- Trial name
- NCT00980655
- Testing
- 13vPnC, 23vPS
- Where
- 47 sites in United States, Belgium and 8 more
- Volunteers
- 251 people
- Sponsor
- Pfizer
Bone Marrow Transplant- Autologous or Allogeneic
Human Breastmilk in Children Receiving a Bone Marrow Transplant
The investigators hypothesize that children receiving human milk will maintain a greater diversity of helpful bacteria in their gut and have lower levels of inflammatory proteins in the blood compared with children not receiving…
- Trial name
- MILK (NCT02025478)
- Testing
- Breastmilk
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Acute Myeloid Leukemia
Mismatched Donor Cells to Treat Acute Myeloid Leukemia
The purpose of this study is to assess the safety and efficacy of infusing immune cells from a donor as treatment for patients with acute myeloid leukemia that is resistant to chemotherapy or who have experienced relapse.
- Trial name
- ATAC-AML-01 (NCT01793025)
- Testing
- ATAC Therapy
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Aplastic Anemia
Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia
The purpose of this study is to reduce the regimen related toxicities and transplantation related mortality after allogeneic stem cell transplantation in adult acquired aplastic anemia (AA), the trials of reduced dose of Cy along…
- Trial name
- CyATG-FluATG (NCT01145976)
- Testing
- Cy-ATG, Flu-ATG
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Cooperative Study Group A for Hematology
Cancer, Sarcoma
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15…
- Conditions
- Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- EBNK-ST-001 (NCT07410676)
- Testing
- EBNK-001 + IL-15 + Pembrolizumab
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Essen Biotech
Leukemia, Myelocytic, Acute
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
The study is designed as a Phase III, multicenter trial comparing outcomes after allogeneic hematopoietic stem cell transplantation (HCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) between patients…
- Trial name
- NCT01339910
- Testing
- Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine
- Where
- 32 sites in United States
- Volunteers
- 272 people
- Sponsor
- Medical College of Wisconsin
Ischemic Heart Disease, Non-ischemic Cardiomyopathy
Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device
A study to assess the safety and preliminary efficacy of serial intravenous dose of Allogeneic Mesenchymal Bone Marrow Cells in subjects with heart failure and implanted left ventricular assist devices.
- Trial name
- STEM-VAD (NCT03925324)
- Testing
- Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Medstar Health Research Institute
Primary Myelofibrosis, Secondary Myelofibrosis
Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
This pilot clinical trial studies the side effects and best dose of ruxolitinib phosphate when given together with chemotherapy before and after a donor stem cell transplant in treating patients with myelofibrosis.
- Trial name
- NCT02917096
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
CMV
Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers
This is an observational cohort study. Two cohort will be enrolled: LMV cohort: All patients included in in this study will receive LMV according to standard of care.
- Trial name
- NCT06211543
- Volunteers
- 80 people
- Sponsor
- Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Graft vs Host Disease, Bronchiolitis Obliterans
Efficacy Study of Azithromycin-based Therapy for Bronchiolitis Obliterans
[Study Objectives] To evaluate the efficacy of azithromycin, N-acetylcystein, and inhaled corticosteroid combination therapy in patients with bronchiolitis obliterans as a complication of allogeneic hematopoietic cell…
- Trial name
- NCT01327625
- Testing
- azithromycin + N-acetylcystein + inhaled corticosteroid
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Asan Medical Center
High Risk Acute Myeloid Leukemia, Allogeneic Hematopoeitic Stem Cell Transplantation
CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML
Aim: To evaluated if cladribine based conditioning (CBA) could decrease relapse after haploidentical allogeneic HSCT in high risk and refractory AML patients as compared with fludarabine based conditioning regimen(FBA).
- Trial name
- NCT03384225
- Testing
- Cladribine, Fludarabine, Busulfan
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2
Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS
To assess the safety and efficacy of FLU-BU-MEL as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with untreated MDS-EB or IPSS-R that is intermediate-risk (>3.5 points), high-risk, or…
- Conditions
- Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Myelodysplastic Syndromes
- Trial name
- NCT06247917
- Testing
- Fludarabine, Busulfan and Melphalan
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Ruijin Hospital
Metastatic Pancreatic Cancer
MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)
Pancreatic cancer is expected to be the second leading cause of cancer-related death in 2020. Pancreatic cancer is known as an immunological cold tumor.
- Trial name
- REACtiVe-2 (NCT05650918)
- Testing
- MesoPher, Mitazalimab
- Where
- Netherlands
- Volunteers
- 22 people
- Sponsor
- Joachim Aerts, MD PhD
Multiple Myeloma, Plasma Cell Leukemia
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Standard therapy for multiple myeloma (MM) usually includes an autologous bone marrow stem cell transplant - a procedure where the patient is treated with high dose chemotherapy and then their own (autologous) stem cells are…
- Trial name
- NCT00615589
- Testing
- Fludarabine/Busulfan x 4 days, stem cell transplant
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Michigan Rogel Cancer Center
A Target Trial Emulation Study, Donor Age
Younger vs. Older Donors in Allo-HSCT: TTE
Hematopoietic stem cell transplantation is an important therapeutic approach for hematologic malignancies, and the impact of donor age on transplant outcomes remains an active area of investigation.
- Conditions
- A Target Trial Emulation Study, Donor Age, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Trial name
- NCT07666568
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Respiratory Tract Diseases
ASC Therapy for Patients With Severe Respiratory COVID-19
The emerging field of stem cell therapy holds promise of treating a variety of diseases. Especially the mesenchymal stromal cells from bone marrow or adipose tissue (ASCs) have proven their potential for regenerative therapy in…
- Trial name
- ASC COVID-19 (NCT04341610)
- Testing
- Stem Cell Product
- Where
- Denmark
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hematopoietic Stem Cell Transplantation, Obliterative Bronchiolitis
Respiratory Impedance and Obliterative Bronchiolitis
The aim of the present study will be to test the hypothesis that changes in within-breath total respiratory input impedance (Zrs) may provide an early evidence of obliterative bronchiolitis after allogeneic hematopoietic stem…
- Trial name
- FOT-BOS (NCT01255449)
- Testing
- albuterol
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Multiple Myeloma (MM), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
Chimeric Antigen Receptor T-Cell (CAR-T) immunotherapy is a rapidly developing novel approach in adoptive immunotherapy for tumors in recent years.
- Conditions
- Multiple Myeloma (MM), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Chimeric Antigen Receptor T-cell
- Trial name
- NCT07034755
- Testing
- autologous hematopoietic stem cell transplantation (ASCT) followed by CAR-T therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
AML/MDS
Innate Donor Effector Allogeneic Lymphocyte Infusion After Stem Cell Transplantation: the IDEAL Trial
The curative principle behind allogeneic hematopoietic stem cell transplantation (HSCT) is eradication of the malignant cells of the patient (recipient) by donor graft cells, a process termed graft-versus-leukemia (GVL) effect.
- Trial name
- IDEAL (NCT05686538)
- Testing
- iDLI
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Pancreatic Cancer
Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00003780
- Testing
- tumor infiltrating lymphocyte therapy, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Meyer Pharmaceuticals